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Abstract: Shingles, also known as herpes zoster, is a common disease in the elderly population 
that is caused by reactivation of latent varicella zoster virus. Its manifestations and complica-
tions can lead to signiﬁ  cant short- and long-term morbidity. In 2006, the United States Food 
and Drug Administration approved Zoster Vaccine Live (Zostavax®) for the prevention of 
herpes zoster in immunocompetent adults age 60 and over. The approval was based on the 
results of a large, multi-center clinical trial, the Shingles Prevention Study. This study showed 
that vaccination signiﬁ  cantly decreased shingles incidence, burden of illness due to disease, 
and the development of, and severity of postherpetic neuralgia. This review offers an overview 
of varicella zoster virus infection and complications, a summary of the Shingles Prevention 
Study, and a critical analysis designed to aid the practicing physician who has questions about 
vaccine administration.
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Introduction
Herpes zoster (HZ) is a highly prevalent disease in the United States with approxi-
mately one million cases diagnosed annually (Insinga et al 2005; Oxman et al 2005). 
The majority of those affected are older individuals; susceptibility to the disease begins 
to increase at age 50 and by age 60 adults are 8 to 10 times more likely to develop 
HZ and signiﬁ  cantly more prone to develop complications than their younger coun-
terparts (Gilden et al 2000; Kimberlin and Whitley 2007). About 30% of people will 
experience at least one episode during their lifetime and this lifetime risk increases 
to 50% if one lives to age 85 (Brisson et al 2001; Dworkin et al 2007). In the Duke 
Established Populations for Epidemiological Studies of the Elderly, a multi-center 
population survey of adults aged 65 and older, the risk of developing HZ increased 
by an odds ratio of 1.2 for every ﬁ  ve-year increase in age after age 65 (Schmader et al 
1995). In 2005, the US Census Bureau reported that 49 million people in the United 
States were 60 years of age or older, a number expected to double by 2030 (USCB 
2004). The World Health Organization deﬁ  nes an elderly person as one who is 65 
years of age or older; and as this population in the United States quickly expands, it 
is probable that HZ will become only more common (WHO 2007).
On May 25th, 2006, the United States Food and Drug Administration (FDA) 
approved Zoster Vaccine Live, a live-attenuated vaccine for varicella-zoster virus 
(VZV). This signaled recognition by health ofﬁ  cials of the need to prevent and com-
bat this disease more effectively. Although licensing of the vaccine was a major step, 
many uncertainties remain regarding the vaccine’s long-term effects, efﬁ  cacy, and 
cost-effectiveness. This review will address these questions, but will ﬁ  rst review the 
pathophysiology and lasting sequelae of HZ, summarize the relevant data and clinical 
trials involving Zoster Vaccine Live, and offer practical recommendations for vaccine 
administration in the elderly patient.Clinical Interventions in Aging 2008:3(2) 242
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Varicella-zoster virus infection
Primary infection
VZV, also known as human herpes virus 3, has a genome 
composed of a single, linear, double-stranded DNA. Upon 
initial infection, the common childhood exanthem known as 
both chicken pox and varicella, is manifested. The derma-
tological signs typically follow a short catarrhal phase and 
consist of numerous vesicles on erythematous bases. These 
are distributed over the entire body in various stages of crust 
formation and healing. It is normally a self-limited, benign 
disease with only rare long-term consequences. In the United 
States, 95.5% of people aged 20–29, 98.9% of people aged 
30–39, and more than 99.6% of people over age forty show 
seropositivity to the virus (Kilgore et al 2003).
Reactivation
Most commonly, after resolution of the primary infec-
tion, VZV remains dormant in sensory nerve root ganglia 
(Opstelten et al 2002). However, reactivation of VZV, 
known as shingles, or HZ, may always occur, and may be 
precipitated by any condition that weakens the immune 
system. Common conditions that increase susceptibility to 
HZ are HIV and AIDS, chronic immunosuppressive therapy, 
radiotherapy, intensely stressful life events, and the normal 
deterioration of cell-mediated immunity associated with 
aging (Gnann and Whitley 2002; Levin et al 2003). An 
epidemiologic study of 786 men clearly demonstrated the 
strong effect of immunosuppression on disease incidence 
by ﬁ  nding that HIV seropositivity conferred a relative risk 
of 16.9 for the development of HZ compared with healthy 
controls (Buchbinder et al 1992). Immunosuppression from 
any cause is believed to increase disease frequency by 20 to 
100 times (Schmader 2007a).
Hope-Simpson (1965) proposed that one possible expla-
nation for the relatively lesser incidence of HZ in immuno-
competent persons is that subclinical reactivations of small 
amounts of latent virus may occur, acting as “boosters” to 
stimulate the immune system. A similar justiﬁ  cation has 
been proposed to explain why secondary episodes of reacti-
vation in immunocompetent persons occur only rarely. The 
ﬁ  rst episode of HZ serves to activate the immune system, 
increasing varicella antibody titers and varicella-speciﬁ  c 
cellular immunity (Taha et al 2006; Kimberlin and Whitley 
2007). A recently published Italian epidiomiologic study of 
26,394 patients aged 14 and over found that over the course 
of one year, 46 cases of HZ were diagnosed (1.74 cases/1000 
population per year; 95% CI: 1.28–2.32); only three (6.5%) 
of the episodes were recurrences and two of the recurrences 
were in immunocompromised patients (Legami et al 2007). 
This increased likelihood of recurrence in patients with 
impaired immunity was also illustrated in a study of 1044 
patients with AIDS, which found that of the 163 with a prior 
history of HZ, 22 (13%) had a recurrence during the two-year 
follow-up (Glesby et al 1993).
Clinically, HZ consists of three distinct stages. The 
prodromal phase lasts for two to three weeks and patients 
experience neuritic pain, parasthesias, or pruritus, generally 
localized to one dermatome. This pain is often mistakenly 
ascribed to the musculoskeletal system as dermatologic 
manifestations have yet to appear. After the prodrome, acute 
vesiculation occurs over a period of three to ﬁ  ve days and 
then subsides with the formation of crusts; this may take up 
to three weeks to occur (Gnann and Whitley 2002). Although 
VZV is most transmissible during episodes of varicella, the 
vesicular lesions of HZ contain high concentrations of virus 
that may cause primary infection in previously unexposed 
individuals (Cohen et al 1999). The vesiculation is most often 
limited to the dermatome that has the highest density of VZV 
although vesiculation may overlap into adjacent dermatomes 
in up to 20 percent of cases (Gnann and Whitley 2002). 
The dermatomes supplied by the trigeminal and thoracic 
nerves are the most frequent sites of reactivation (Cohen 
et al 1999). The pain associated with the vesicular stage is 
clinically signiﬁ  cant, a recent study of 160 adults age 60 and 
older demonstrated that 73% of subjects still complained of 
moderate to severe pain seven days after initial presentation. 
66.7% of subjects reported that the pain interfered with their 
enjoyment of life, 58.3% said that it interrupted their daily 
activities, and ~20% had difﬁ  culties with activities of daily 
living (Schmader et al 2007b). The third clinical stage, if it 
occurs, is the development of post-herpetic neuralgia (PHN). 
PHN has multiple deﬁ  nitions, but is commonly deﬁ  ned as 
neuritic pain that persists in the area of the affected derma-
tome after the rash has healed, or pain that lasts at least 30 
days from the onset of lesions (Young 2006).
Post-herpetic neuralgia
Although PHN does not occur in every case of HZ, it is still 
the leading cause of long-lasting morbidity after resolution 
of the acute outbreak. Its likelihood of developing increases 
with the age of the patient. In one report, at least 40% of 
patients over age 60, and 75% over age 70 developed PHN 
following an episode of HZ (Vander Straten et al 2001). In 
comparison, multiple studies have suggested that children 
and adolescents have either no risk, or an extremely low 
risk of developing the condition (Petursson et al 1998; Clinical Interventions in Aging 2008:3(2) 243
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Opstelten et al 2002). PHN can last from weeks to years, 
and is frequently extremely debilitating. This fact is high-
lighted by a recent study using the Short-form McGill Pain 
Questionnaire in which patients rated the chronic pain 
associated with PHN to be more severe than pain associ-
ated with rheumatoid arthritis or chronic cancer (Katz and 
Melzack 1999).
Although there have been many trials testing the 
efﬁ  cacy of treatments for PHN, ranging from antiviral 
therapy (Wood et al 1994l; Kost and Straus 1996), to ste-
roids (Eaglestein et al 1970; Keczkes and Basheer 1980; 
Esmann et al 1987), to dopamine agonists (Galbraith 
1983), to antiepileptic agents (Rowbotham 1998; Rice 
and Maton 2001; Tassone et al 2007), no treatment has 
adequately shown a reduction in incidence and the pain 
relief achieved is not close to satisfactory. There have 
been no controlled trials in which complete pain relief has 
been achieved. Currently, gabapentin, pregabalin, and the 
topical lidocaine patch are FDA-approved for the treatment 
of PHN (Schmader 2007a). These therapies, along with 
nortriptyline, opiods, and tramadol, are generally used as 
ﬁ  rst-line treatments and some degree of pain relief may 
be expected in 30%–60% of treated patients (Schmader 
2007a). A more detailed analysis comparing the therapeutic 
effectiveness of agents used to treat PHN may be found in 
multiple recently published reviews (Young 2006; Saarto 
and Wiffen 2007; Schmader 2007a).
PHN is an especially troubling complication in the elderly 
population where pain medications offer their own set of 
risks and adverse effects. Pain control is more difﬁ  cult to 
achieve in elderly individuals and they are also more likely 
to experience the adverse effects of new medications due to 
age related changes in pharmacokinetics and pharmacody-
namics. In addition, the elderly are more likely to require 
hospitalization due to these adverse effects than their younger 
counterparts (Caranasos et al 1974).
Complications of VZV infection
In addition to PHN, infection with VZV may lead to other 
serious, but rare, complications. These include bacterial 
superinfection, viral dissemination, myelitis, encephalitis, 
and peripheral and cranial nerve palsies (Galil et al 1997; 
Hausler et al 2002; Im et al 2007; Kawajiri et al 2007). Reac-
tivation in the ophthalmic region of the trigeminal nerve may 
lead to blindness, and infection of the geniculate ganglion 
to facial weakness and occasional hearing disorders (Adour 
1994; Garweg and Bohnke 1997). The majority of these 
complications have very limited treatment options. With our 
current technologies, it is clear that the most effective way 
to combat them is by preventing both initial infection and 
reactivation of VZV.
The VZV vaccine
Varivax
The ﬁ  rst VZV vaccine, Varivax®, was approved by the FDA 
in 1995 as a method for preventing primary infection with 
VZV. Routine vaccination programs with Varivax have been 
implemented since that time. Varivax is made of the same 
strain of live-attenuated VZV as found in Zoster Vaccine 
Live, but contains a much lower dose of virus (Table 1). 
The dose of the vaccine is determined by the number of 
plaque-forming units (PFU) of virus that it contains; the 
monovalent formulation of Varivax contains 1,350 PFU and 
the quadrivalent formulation, in which Varivax is combined 
with vaccinations for measles, mumps, and rubella, contains 
9,772 PFU. The Oka strain of VZV, used in both vaccines, 
was acquired from the vesicles of a three-year old Japanese 
boy infected with VZV and attenuated through multiple 
laboratory procedures. The vaccine was initially given as 
one dose to children aged 12–18 months or to any other indi-
vidual deemed at risk, but follow-up studies have suggested 
that in vaccinated individuals, immunity to VZV may wane 
over time (Chaves et al 2007b). For this reason, the Center 
for Disease Control (CDC) recently modiﬁ  ed its schedule 
to recommend two doses of the vaccine and to include 
any healthy adult lacking evidence of immunity within its 
recommendations (Marin et al 2007). Since the vaccination 
program was begun, the United States has experienced a 
substantial reduction in morbidity, mortality, and health care 
costs associated with chicken pox (Davis et al 2004; Nguyen 
et al 2005). Despite these successes with chicken pox, a 
reduction in HZ disease burden has yet to be seen. Because 
the majority of older individuals living today have already 
been exposed to VZV, and thus are carriers of latent virus, 
they remain susceptible to the development of HZ.
A vaccine for patients seropositive 
for VZV
Although it is unclear what speciﬁ  cally occurs to allow a 
reactivation of VZV, general belief is that a gradual reduction 
in cell-mediated immunity against VZV occurs over time 
after primary infection. When immunity reaches a critically 
low level, reactivation may occur. It has been postulated that 
individuals exposed to active cases of VZV in others may 
experience a boost in their own immunity against VZV that Clinical Interventions in Aging 2008:3(2) 244
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will help to suppress reactivation of the virus (Hope-Simpson 
1965). With this concept in mind, preliminary trials examining 
the use of Varivax in patients already seropositive for VZV 
were undertaken. Initial data suggested that the number of 
PFU required to elicit a signiﬁ  cant increase in cell-mediated 
immunity against VZV would have to be at least 14 times 
greater than the PFU found in the monovalent formulation of 
Varivax (Levin 2001). The efﬁ  cacy of a more potent vaccine 
in preventing HZ in VZV seropositive subjects was examined 
in the nationwide Shingles Prevention Study (SPS).
The shingles prevention study
Study design
The SPS was a randomized, double-blind, placebo-controlled 
study, conducted by the Department of Veterans Affairs, 
designed to test the effectiveness of the live-attenuated 
Oka/Merck VZV vaccine for preventing HZ in adults aged 
60 and older. The primary endpoint of the study was reduc-
tion in burden of illness, deﬁ  ned as a severity-by-duration 
measure of the total pain and discomfort associated with 
HZ. The secondary endpoint was the incidence of PHN and 
other endpoints included incidence of HZ, and the severity 
of illness. 38,546 subjects were enrolled at 22 different sites 
and were randomly assigned to receive vaccine or placebo 
(Oxman et al 2005). To be eligible for participation, subjects 
must have had a history of primary VZV infection or have 
resided in the continental United States for over 30 years. 
Immunocompromised patients, those with a history of prior 
HZ, and those unable to adhere to study protocol were 
excluded from the study.
At the onset of the study participants were educated 
about the signs and symptoms of HZ and were counseled to 
contact their study site immediately if they developed a new 
rash or unilateral pain. Subjects were given a subcutaneous 
injection of either 0.5 ml of the zoster vaccine or placebo. 
12 different vaccine lots were used, varying in potency from 
18,700 PFU (~14 times the potency of Varivax) to 60,000 
PFU per dose. The median potency was 24,600 PFU with 
more than 90% of those vaccinated receiving 32,300 PFU 
or less (Oxman et al 2005).
Throughout the length of the study, subjects called in to 
an automated telephone-response system at speciﬁ  ed time 
intervals and were asked a series of standardized questions 
designed to identify possible cases of HZ. If a suspected case 
was identiﬁ  ed by certain answers, they were instructed to con-
tact their local study site immediately. In clinically suspected 
cases of HZ, a conﬁ  rmation of diagnosis was made by viral 
culture and polymerase-chain reaction assay performed by 
one central laboratory. If testing was inconclusive, a team 
of ﬁ  ve physicians, blinded to the subject’s vaccination status 
and with an expertise in HZ, made the ﬁ  nal determination of 
disease status (Oxman et al 2005).
Table 1 Comparison of Zoster Vaccine Live (Oxman et al 2005; Merck 2007) and Varivax® (Marin et al 2007)
Zoster Vaccine Live Varivax®
Year of licensure 2006 1995
Vaccine dose At least 19,400 PFU 1,350 PFU
Vaccine strain Live-attenuated Oka/Merck VZV Live-attenuated Oka/Merck VZV
Immunization population Immunocompetent individuals age 
60 and older
Vaccination schedule: 1st dose in children 12–15 months old; 
2nd booster dose at age 4–6. Booster dose should be given 
to anyone that has only received one dose regardless of age. 
Seronegative individuals age 13 and older should receive 
immunization.
Effectiveness of vaccination Vaccination provides: 70%–90% effective in disease prevention
Decrease in burden of illness by 
61.1%
Decrease in incidence of posther-
petic neuralgia by 66.5%
Decrease in incidence of herpes 
zoster by 51%
Incidence of serious adverse Events 1.4% in the Shingles Prevention 
Study
0.0026% in post-marketing surveillance
Known duration of protection At least four years, long-term 
duration unknown
One dose: 7–10 years Two doses: Increases effectiveness of 
disease protection to 98.3% at 10 years
Abbreviations: PFU, plaque-forming units; VZV, varicella-zoster virus.Clinical Interventions in Aging 2008:3(2) 245
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All subjects with a diagnosis of HZ were required to 
complete the Zoster Brief Pain Inventory, a questionnaire 
designed speciﬁ  cally to measure the pain and discomfort 
associated with HZ. This questionnaire and others were used 
to examine the effects of HZ infection on daily living, qual-
ity of life, and general health status. During result analysis 
subjects were stratiﬁ  ed by age into one group aged 60–69 
and another aged 70 and older. All adverse events occurring 
within 42 days of vaccination were recorded and all serious 
adverse events reported by the subject and deemed by the 
physician to be related to vaccination were recorded through-
out the length of the study (Oxman et al 2005).
Results
Subjects were followed for a mean duration of 3.13 years 
(range, 1 day to 4.90 years) and 95% of participants com-
pleted the trial. Subjects who withdrew or developed cases 
of HZ within the ﬁ  rst thirty days following vaccination were 
excluded from the study results. During the study a total of 
960 cases of HZ were conﬁ  rmed, three were excluded from 
data analysis because they were the second episode for a 
subject within the trial period. Of the remaining cases, 642 
occurred in the placebo group and 315 in the vaccinated 
group. Vaccination was shown to signiﬁ  cantly reduce the 
burden of illness (P  0.001) with a relative reduction in 
burden of illness in vaccination group compared with pla-
cebo of 61.1% (95% conﬁ  dence interval [CI], 51.1 to 69.1) 
(Table 2). The rate of use of antiviral medication (87.3% 
in the vaccine group and 85.7% in the placebo group) and 
the percentage of subjects who received it within 72 hours 
(64.1% in the vaccine group and 65.9% in the placebo group) 
were similar between the two groups.
Of the 107 cases of post-herpetic neuralgia that devel-
oped, 27 were in the vaccine group and 80 were in the pla-
cebo group (0.46 case vs. 1.38 cases per 1000 person-years, 
respectively; P  0.001) with vaccination giving a relative 
reduction of 66.5% (95% CI, 47.5 to 79.2) (Table 2). The 
incidence of PHN was more signiﬁ  cantly reduced in the 70 
and older age group than in the 60–69 age group (Oxman 
et al 2005). The overall incidence of HZ was signiﬁ  cantly 
reduced from 11.12 per 1000 person years to 5.42 per 1000 
person years (P  0.001), a relative reduction of 51.3% (95% 
CI, 44.2 to 57.6) (Table 2). Further analysis showed that the 
vaccine was much more effective at preventing HZ in 60–69 
year olds than it was in those 70 and older. The mean HZ 
severity of illness score in the vaccine group was signiﬁ  cantly 
lower than in the placebo group (141.2 vs. 180.5, P = 0.008) 
and the mean duration of pain was also signiﬁ  cantly less 
(21 days versus 24 days, P = 0.03). Medications to treat pain 
associated with HZ were used with equal frequency among 
the two groups. The authors reported that the placebo group 
on average used a greater amount of opiods for a longer 
period of time, though data and statistics were not presented 
(Oxman et al 2005).
Adverse events
The overall incidence of serious adverse events was not sta-
tistically different between the vaccine and placebo groups 
in the SPS as a whole (255 subjects, 1.4% and 254 subjects, 
1.4% respectively). Study coordinators determined that out 
of all serious adverse events, two in the vaccine group and 
three in the placebo group were possibly vaccine-related. 
Two days after receiving the vaccine a 64-year-old had an 
asthma exacerbation and after three days an 80-year-old 
developed symptoms of polymylagia rheumatica. Of those 
who received placebo, one 65-year-old had an anaphylactic 
reaction 90 minutes later, a 69-year-old was diagnosed with 
polymalgia rheumatica after 15 days, and a 78-year-old was 
diagnosed with Goodpasture’s syndrome on day 52 post 
injection (Oxman et al 2005).
6616 subjects were enrolled in an adverse events moni-
toring substudy; these subjects were followed more closely 
for adverse events with the use of report cards and active 
monthly surveillance. In this sub-study, the risk of a seri-
ous adverse event within 42 days of vaccination was 1.3% 
in the placebo group compared with 1.9% in the vaccine 
Table 2 Shingles Prevention Study summary (Oxman et al 2005)
  Vaccine group  Placebo group  Relative reduction in vaccine
      group compared with placebo
     (95%  conﬁ  dence interval, P  0.001)
Incidence of herpes zoster  315 cases/19,254 subjects  642 cases/19,247 subjects  51.3% (44.2–57.6)
Incidence of postherpetic neuralgia  27 cases/19,254 subjects  80 cases/19,247 subjects  66.5% (47.5–79.2)
Burden of illness due to herpes zoster*  2.21  5.68  61.1% (51.1–69.1)
Notes: *Burden of illness is a severity by duration measure of the total pain and discomfort experienced during an episode of herpes zoster. A numerical representation is 
calculated based upon a study subject’s answers to the Zoster Brief Pain Inventory.Clinical Interventions in Aging 2008:3(2) 246
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group, an increased relative risk of 1.53 (95% CI, 1.04 to 
2.25). Those in the vaccine group were also 31.7% more 
likely to experience a vaccination site reaction than those in 
the placebo group. Many vaccinated subjects experienced 
erythema (1188 subjects, 35.8%), pain or tenderness (1147 
subjects, 34.5%), swelling (871 subjects, 26.2%), and pruritus 
(237 subjects, 7.1%) at the injection site. There was a 0.1% 
incidence of varicella-like rashes at the injection site of vac-
cine recipients compared with 0.04% of placebo recipients 
(P  0.05) (Oxman et al 2005).
Clinical use
The SPS offered extremely promising results and after 
FDA-approval, the CDC issued its recommendation that 
individuals 60 and older be vaccinated. The Advisory Com-
mittee on Immunization Practices (ACIP) expanded upon 
the recommendations of the CDC to clarify that vaccination 
should be provided to eligible individuals even if they do not 
have a history of primary clinical infection, if they were born 
United States before 1980 (and may therefore be considered 
seropositive for VZV) (Marin et al 2007). In addition, even 
though the SPS did not include subjects with histories of 
prior HZ, the ACIP also recommended that these individu-
als be included in any HZ vaccination program (Marin et al 
2007). Preliminary analysis has shown that based on a cost 
of US$150 per vaccine dose, estimated cost per quality-
adjusted life for Zoster Vaccine Live is comparable with 
that of the pneumococcal vaccine, already in widespread 
use among the elderly population (Messonnier and Zhou 
2006). 18 people would need to be vaccinated in order to 
prevent one case of HZ and 109 people would need to be 
vaccinated to prevent one clinically signiﬁ  cant case of PHN 
(Oxman 2007).
Physicians planning to administer the vaccine must 
have the capability to store the vaccine at −15 degrees 
Celsius (+5 degrees F). The distributed vaccine has been 
formulated to contain a minimum of 19,400 PFU in a 
0.65 ml dose (a 0.5 ml formulation was used in the SPS). 
It should be administered by subcutaneous injection no 
longer than thirty minutes after reconstitution with pro-
vided diluent and discarded if not used within this time. 
Physicians should also be aware that the vaccine is not 
approved for use in anyone with innate or acquired immu-
nodeﬁ  ciency because it is a live vaccine. The vaccine is 
contraindicated in pregnant women, people with untreated, 
active tuberculosis, those with a history of anaphylactic 
reactions to gelatin, neomycin, or any other vaccine com-
ponent, and people with any type of immunodeﬁ  ciency or 
those on immunosuppressive therapy (Table 3). The ACIP 
recommends that persons chronically taking more than 
2 mg/kg per day of corticosteroids or those on 20 mg/day 
of prednisone for two weeks or more should be considered 
immunosuppressed and should not receive the live vaccine 
(Kroger et al 2006).
Transmission of the vaccine virus was not reported 
in the SPS, and vaccine virus was not isolated from any 
immunized study participants who developed rashes, 
including those with a varicella-like presentation (Oxman 
et al 2005). However, the vaccine labeling warns that 
transmission of the vaccine virus may occur between 
Table 3 Prescription recommendations for Zoster Vaccine Live
Is Zoster Vaccine Live appropriate for my patient?
1) Is my patient 60 years of age or older?
Zoster Vaccine Live is only FDA-approved for use in patients 60 and above.
2) Does my patient have any characteristic for which administration of a live vaccine could be unsafe?
Any condition or situation that compromises a patient’s immune system is a contraindication to vaccine administration. This includes:
•  Chronic immunosuppressive therapy such as chemotherapy or high-dose corticosteroids.
•  Any primary or acquired immunodeﬁ  ciency state, including AIDS.
•  Neoplasms affecting the bone marrow or lymphatic system.
•  Active, untreated tuberculosis.
3) Does my patient have a history of anaphylactic reaction to any vaccine component?
Zoster Vaccine Live contains gelatin and neomycin, along with many other ingredients. A history of neomycin-induced contact dermatitis is not a 
contraindication to vaccination.
4) Is my patient pregnant?
Patients should wait four weeks after vaccination to conceive and should not be vaccinated while pregnant.
5) My patient is currently suffering from postherpetic neuralgia. Will vaccination relieve his/her symptoms?
Zoster Vaccine Live is indicated for the prevention of herpes zoster and its complications. It is not a treatment for active cases of herpes zoster or 
postherpetic neuralgia.Clinical Interventions in Aging 2008:3(2) 247
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vaccinees who develop a varicella-like rash and sus-
ceptible contacts (Merck 2007). Eight separate cases of 
possible transmission have been reported during post-
licensure safety surveillance though no serious clinical 
consequences have been noted (Chaves 2007a). Physicians 
should warn patients, even those who do not develop a 
varicella-like rash, of the small but deﬁ  nite risk of trans-
mitting the virus to varicella-susceptible individuals, 
especially those who may develop serious adverse effects 
from contraction of the virus such as pregnant women and 
unvaccinated infants.
Discussion
The SPS provides solid evidence that vaccination with Zoster 
Vaccine Live signiﬁ  cantly reduces the burden of illness of 
HZ, the incidence and severity of PHN, and the incidence 
of HZ in people age 60 and older. This news comes at an 
especially critical time as our elderly population, and hence 
the number of people at risk for the development of HZ, is 
quickly expanding. According to the results of the SPS, if a 
routine immunization program were properly implemented, 
up to 250,000 cases of HZ may be prevented every year 
(Burke 2007). There have been multiple published cost-
effectiveness analyses since the reporting of the SPS results. 
One, which was carried out using data from the SPS, and a 
commonly accepted cost-effectiveness threshold of $50,000 
per quality-adjusted life year gained, was presented at the 
ACIP’s 2006 meeting; it demonstrated that vaccination 
is cost-effective for immunocompetent adults age 60 and 
older (Pellisier 2006). Another initial analysis using similar 
criteria suggested that the annual economic cost of a vac-
cination program may exceed the cost of annual HZ infec-
tions (Hornberger and Robertus 2006). An additional article 
demonstrated that cost-effectiveness varies signiﬁ  cantly with 
sex and with age at time of vaccination (Rothberg et al 2007). 
This study suggests that cost-effectiveness may range from 
an acceptable US$44,000 per quality-adjusted life year saved 
for a 70-year-old woman to US$191,000 per quality-adjusted 
life year saved for an 80-year-old man (Rothberg et al 2007). 
However, until more time has passed, and information on 
length of vaccine efﬁ  cacy is documented, this issue cannot 
be deﬁ  nitively resolved. Furthermore, along with budgetary 
implications, the societal beneﬁ  ts offered by any vaccination 
program must also be considered. With successful vaccina-
tion against HZ, there will be decreased risk of transmission 
of VZV to seronegative persons, increased productivity in 
the work force as burden of illness and incidence are both 
signiﬁ  cantly reduced, and with each case of HZ resulting in 
an average of two outpatient doctor’s visits, reduced strain 
on an already overwhelmed healthcare system (Hornberger 
and Robertus 2006).
Vaccination against HZ is also particularly relevant today 
as a routine immunization program with Varivax, to prevent 
primary VZV infection, has been implemented. The number 
of primary VZV infections has been reduced by 70%–90% 
and concern has been raised that HZ incidence will rise in 
elderly persons who will no longer experience frequent 
exposures to VZV (Chaves et al 2007c; Marin et al 2007). 
This concept was recently investigated in a countrywide 
population survey of 3,675 individuals aged 65 and older 
that attempted to objectively determine whether exposure 
to primary VZV infection reduced the risk of HZ (Chaves 
et al 2007c). The survey found no statistical difference in HZ 
incidence in those that had been exposed to chickenpox in 
the past decade and those who had not. However, the study 
was ﬂ  awed in that it depended on the self-reporting by elderly 
individuals in regards to HZ incidence and chickenpox expo-
sure and its clinical relevance was limited by the fact that 
it did not take disease severity or the development of PHN 
into consideration (Chaves et al 2007c). The most recently 
conducted epidemiological study of the general popula-
tion examining HZ incidence took place from 2000–2001, 
ﬁ  ve years after the FDA-approval of Varivax (Insinga et al 
2005). Although there was no increase in incidence of HZ 
compared with studies from 10–20 years earlier, widespread 
administration of Varivax had only just begun, in 1997 vac-
cination coverage among children 19–35 months was only 
27%, and the long-term effects of childhood vaccination on 
HZ incidence may yet to be seen (Insinga et al 2005; Marin 
et al 2007).
Although the existing evidence is extremely persua-
sive to promote routine vaccination for those ages 60 and 
older, uncertainties do remain. As any clinician knows, 
the elderly patient often has many existing comorbidities. 
In the SPS however, only 6.5% of study subjects were 80 
years of age or older, only about 11% had diabetes mellitus, 
and most subjects with COPD were excluded because of 
corticosteroid use. Thus safety and efﬁ  cacy data in these 
groups, which make up a large population of most practices, 
is limited.
Another unanswered question is how long the protective 
effect of Zoster Vaccine Live will last. The SPS demon-
strated a length of protection of at least four years, but it is 
possible that it is effective for a great deal longer (Oxman 
et al 2005). The length of vaccine effect could be inﬂ  uenced 
by multiple factors including the vaccine dose, as well as Clinical Interventions in Aging 2008:3(2) 248
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the subject’s age and health status. Participants in the SPS 
received varying dosages of vaccine but the analysis of 
data did not examine whether those who received higher 
doses experienced fewer episodes of HZ, or whether they 
succumbed to more adverse events. An intriguing study 
was recently performed in the United States, Canada, and 
Europe. It compared the safety proﬁ  le of two VZV vac-
cines, one containing 58,000 PFU of the live-attenuated 
Oka/Merck strain (slightly higher than the median number 
of PFU in the SPS) and the other with 207,000 PFU (Tyring 
et al 2007). 698 subjects, aged 50–90 were enrolled, and 
clinically acceptable tolerability was predeﬁ  ned based on 
experiences with PNEUMOVAX 23®, another vaccine 
routinely administered to this age group. Although the rate 
of injection-site adverse events was greater in the group 
receiving higher doses, it did not exceed the prespeciﬁ  ed 
criteria for clinically acceptable tolerability. This result is 
promising on two different fronts; ﬁ  rst, as time passes and 
our experience with Zoster Vaccine Live grows, we may 
ﬁ  nd that the provided immunity to HZ wanes with time. This 
study offers evidence that large-scale trials with even higher 
doses of the vaccine may be employed to attempt to confer 
longer-lasting protection. Second, this trial included adults 
aged 50–59, a group which was excluded from the SPS. 
Although patients aged 60 and older are the most likely to 
develop HZ, the incidence of HZ ﬁ  rst begins to rise after 50 
years of age. Since the completion of the SPS, questions have 
been raised regarding the applicability of the CDC recom-
mendations to those aged 50–59. Although this study show 
a higher percentage of injection-site reactions in the 50–59 
age group compared with the 60 and older age group, no 
person in either group experienced a serious adverse event 
related to the vaccine during the study. Further follow-up 
needs to be undertaken to determine whether vaccination 
is efﬁ  cacious and cost effective in adults age 50–59. There 
is a possibility that a more robust immune response in this 
age group may lead to higher rates of long-lasting protective 
immunity following vaccination.
HZ is seen with greater frequency in immunocompro-
mised people; this group was excluded from the SPS due 
to safety concerns regarding administration of a live virus. 
The seriousness of this threat has been conﬁ  rmed with 
reported cases of severe Oka strain VZV infection in a 
heart transplant recipient (Kraft and Shaw 2006), an HIV 
positive patient (Kramer et al 2001), and a patient with a 
primary deﬁ  ciency in natural killer T cells (Levy et al 2003) 
among others. These cases are clear examples of how the 
attenuated vaccine virus has the potential to become latent 
and later reactivate to cause vaccine virus strain (Oka-strain) 
HZ (Takayama et al 2000). In cases where disease course or 
treatment allows a physician to predict a future deterioration 
in immune status, it remains to be seen whether preemp-
tive vaccination will be safe or efﬁ  cacious in reducing the 
incidence of HZ. One recent study examined the use of a 
heat-inactivated VZV vaccine before and after hematopoi-
etic-cell transplantation for Hodgkin’s or Non-Hodgkin’s 
lymphoma in 111 patients (Hata et al 2002). In this small 
trial, the incidence of HZ was signiﬁ  cantly reduced in vac-
cinated patients and vaccine-related adverse events were 
limited to injection site reactions (Hata et al 2002). These 
results suggest that the use of heat-inactivated virus vaccine 
may be effective and safe in immunocompromised patients 
and additional trials should be undertaken in other, more 
varied populations.
Until more time has passed, and regular use of Zoster 
Vaccine Live has been instituted throughout the country, the 
uncertainties regarding length of vaccine efﬁ  cacy, the possible 
need for second “booster” shots, and the cost-effectiveness of 
a routine vaccination program cannot be fairly or completely 
addressed. The results of the SPS are extremely promising 
and convincing enough to persuade the CDC and the FDA 
to act upon them. This large, well-designed clinical trial sup-
ports the effectiveness of Zoster Vaccine Live in preventing 
ﬁ  rst episodes of HZ and signiﬁ  cantly reducing the burden 
of illness in adults aged 60 and older. Just as importantly, 
vaccination decreased the incidence and severity of PHN, 
one of the most troublesome aspects of HZ. The data from 
the SPS, along with the vaccine’s safety proﬁ  le, relatively 
low-cost, and ability to prevent considerable pain and suf-
fering in elderly individuals, lead us to offer our support for 
the prescription of Zoster Vaccine Live to immunocompetent 
adults aged 60 and over.
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